EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
|
EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Takeover/Mergers & Acquisitions
Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
15-Dec-2023 / 17:43 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C. |
Jena, December 15, 2023
Carl Zeiss Meditec AG (ISIN: DE0005313704) announces today that it has entered into a definitive agreement to acquire 100% of the shares in Dutch Ophthalmic Research Center (International) BV, Zuidland, Netherlands (D.O.R.C.), from the investment firm Eurazeo SE, Paris, France (ISIN: FR0000121121). D.O.R.C. is a leading company in the vitreo-retinal surgery segment with close to EUR 200 million in revenue expected in fiscal 2023 and an operating profit in the mid double digit million EUR range. The acquisition will enhance and compliment Carl Zeiss Meditec’s ophthalmic portfolio for addressing a wide variety of eye conditions, including retinal disorders, cataracts, glaucoma and refractive errors.
The acquisition is expected to close in the first half of calendar year 2024 subject to applicable regulatory and antitrust approvals. The transaction is valued at an enterprise value of approximately EUR 985 million. The purchase price will be paid for primarily by available net liquidity of Carl Zeiss Meditec AG. In order to maintain operational flexibility, the company plans to seek a shareholder loan from Carl Zeiss AG in the amount of EUR 400 million as part of the financing, with a duration of three years and market-standard conditions.
The acquisition should achieve a modest positive contribution (by a single digit percentage amount) to the earnings per share of Carl Zeiss Meditec AG in the first full year after closing. |
| |
Contact for investors and press
Sebastian Frericks
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: [email protected]
End of Inside Information
15-Dec-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
|
| Language: |
English |
| Company: |
Carl Zeiss Meditec AG |
|
Göschwitzer Str. 51-52 |
|
07745 Jena, Germany |
|
Germany |
| Phone: |
+49 (0)3641 220-0 |
| Fax: |
+49 (0)3641 220-112 |
| E-mail: |
[email protected] |
| Internet: |
www.zeiss.de/meditec-ag/ir |
| ISIN: |
DE0005313704 |
| WKN: |
531370 |
| Indices: |
MDAX, TecDAX |
| Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1798059 |
| |
| End of Announcement |
EQS News Service |
1798059 15-Dec-2023 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Umsatzerlöse1 |
1.189,90 |
1.280,86 |
1.459,32 |
1.335,45 |
1.646,79 |
1.902,84 |
2.089,30 |
| EBITDA1,2 |
205,07 |
228,41 |
313,03 |
237,98 |
435,20 |
466,65 |
422,19 |
| EBITDA-Marge3 |
17,23 |
17,83 |
21,45 |
17,82 |
26,43 |
24,52 |
|
| EBIT1,4 |
180,83 |
197,13 |
264,66 |
177,55 |
373,61 |
396,88 |
348,12 |
| EBIT-Marge5 |
15,20 |
15,39 |
18,14 |
13,30 |
22,69 |
20,86 |
16,66 |
| Jahresüberschuss1 |
135,78 |
126,23 |
160,58 |
123,42 |
237,52 |
295,91 |
292,01 |
| Netto-Marge6 |
11,41 |
9,86 |
11,00 |
9,24 |
14,42 |
15,55 |
13,98 |
| Cashflow1,7 |
37,73 |
187,21 |
219,63 |
178,53 |
362,66 |
188,20 |
250,86 |
| Ergebnis je Aktie8 |
1,57 |
1,41 |
1,79 |
1,37 |
2,64 |
3,29 |
3,25 |
| Dividende8 |
0,55 |
0,55 |
0,65 |
0,50 |
0,90 |
1,10 |
0,42 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PricewaterhouseCoopers
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Carl Zeiss Meditec |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| 531370 |
54,650 |
Halten |
4.887,93 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 18,22 |
33,85 |
0,56 |
26,79 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 2,37 |
19,48 |
2,34 |
9,51 |
| Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23
in % |
Hauptversammlung |
| 1,10 |
1,10 |
2,01 |
21.03.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 09.02.2024 |
08.05.2024 |
06.08.2024 |
11.12.2024 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| -10,85% |
-31,80% |
-44,71% |
-37,18% |
|
|
Carl Zeiss Meditec AG DE0005313704